Oncology

Interferon therapy not recommended for patients with minimal cancer in one lymph node.

Jury orders Johnson & Johnson to pay $72 million in damages to the family of a woman who died from ovarian cancer allegedly caused by products containing talcum powder.

Proposal includes giving insurers the ability to withhold products from formularies if the cost of cancer drugs do not represent good value.

Study finds cancer patients need better support following treatment.

Enzalutamide (Xtandi) capsules treats patients with metastatic castration-resistant prostate cancer.

Dasatinib and demcizumab reduces lung adenocarcinomas and improves survival rates in lung cancer treatment.

Nanoparticle designed to directly hit tumors with a toxic cancerous drug without harming healthy tissue.

Palbociclib (Ibrance) approved for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.

Ibrance approved for the treatment of HR+, HER2- advanced or metastatic breast cancer.

Antibody-drug conjugates and immunotherapy harness immune system to target breast cancer tumors.

Hysterectomies can reduce the risk for ovarian cancer but it can lead to surgical menopause.

Treatments approved for heart failure, cardiac arrhythmia, and infections offer epigenetic effects in cancer therapy.

Top news of the week in oncology medication development.

Recent increases in the number of therapies indicated for a given oncology subtype has resulted in heightened utilization management stringency.

Most read articles of the week on Specialty Pharmacy Times.

Diabetes and other conditions are also influenced by a person’s height.

Gilotrif shows significant reduction in the risk of adenocarcinoma progression.

Inherited genetic variations leave acute lymphoblastic leukemia patients sensitive to drugs and at risk for toxicity.

Enhanced tumor analysis can help identify individual therapeutic cancer strategies.

Issues with learning and paying attention associated with intensive chemotherapy for leukemia.

Durvalumab and tremelimumab demonstrated antitumor activity in patients with non-small cell lung cancer regardless of PD-L1 status.

Durvalumab and tremelimumab demonstrated antitumor activity in patients with non-small cell lung cancer regardless of PD-L1 status.

Numerous canine breeds develop cancers such as breast cancer and melanoma that have genetic similarities with the human equivalent disease.

Research could lead to the development of new cancer treatments.

Top news of the week in oncology drug development.

Gilotrif shows significant reduction in the risk of adenocarcinoma progression.

Cancer treatment advances are now moving to the clinic with great promise, just as precision therapy and immunotherapy are transforming cancer therapy itself.

Investigators seek to stop women's cancers before it starts to form.

Nearly 40% of US employees have no access to paid sick leave.

Study assessed chemotherapy use in patients with chronic myelogenous leukemia (CML) to determine how use of CML-specific tests impacted drug selection and modification.